Rabeximod Crystallization Process for GMP-Scale Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing rabeximod are not suitable for large-scale synthesis and do not meet Good Manufacturing Practice (GMP) standards, limiting their scalability and quality control.
Innovation Solution
A process involving the reaction of 9-chloro-2,3-dimethyl-6H-indolo[2,3-b]quinoxaline with 2-Chloro-N-(2-dimethylaminoethyl)acetamide in the presence of an aqueous base and optional catalyst, using specific solvents and conditions to achieve large-scale production of rabeximod, which can be purified to a crystalline free base form suitable for pharmaceutical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a small-scale lab process is used to prepare rabeximod, then the yield is 58%, but the process cannot be scaled up to large-scale or industrial-scale production
Solution Approach 1:
The patent modifies reaction parameters including solvent selection (acetonitrile, ethyl acetate, toluene, THF), base type (aqueous NaOH, KOH, CsOH, or organic bases like DIPEA, TEA), temperature ranges (20-100°C), and molar ratios to enable scalable production while maintaining yield above 58% and achieving GMP compliance
Solution Approach 2:
The optimized process uses universally applicable reagents and conditions that can be implemented across different production scales from 200g to industrial scale (10kg+), making the process adaptable and reliable for GMP manufacturing without requiring scale-specific modifications
2Reliability
If the small-scale process is used, then rabeximod can be produced, but it does not meet Good Manufacturing Practice (GMP) standards
Solution Approach 1:
The synthesis is divided into discrete, controlled steps with defined intermediate purification stages, allowing each step to be optimized and monitored independently for GMP compliance while maintaining overall process efficiency and manufacturability
Solution Approach 2:
The patent employs specific intermediates with well-defined structures and purification protocols that serve as quality control checkpoints, enabling GMP-compliant manufacturing through standardized intermediate handling and characterization
3Productivity
If the process is scaled up to large-scale production, then industrial production is enabled, but maintaining high yield and purity becomes challenging
Solution Approach 1:
The process incorporates monitoring and control mechanisms that track reaction progress, intermediate quality, and final product purity, allowing real-time adjustments to maintain high yield and purity even at large production scales of 10kg and above
Solution Approach 2:
The patent performs preliminary optimization of reaction conditions, solvent ratios, and purification parameters at smaller scales before scaling up, establishing proven protocols that ensure high yield and purity are maintained when transitioning to industrial-scale production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process enables the production of rabeximod in high yield and purity, suitable for industrial-scale synthesis and compliant with GMP standards, facilitating its use in pharmaceutical formulations for treating autoimmune diseases.
Implementation Method 1
reacting a solution or suspension of 9-chloro-2,3-dimethyl-6H-Indolo[2,3-b] quinoxaline in the presence of an aqueous base sufficiently strong to deprotonize the indole N—H
Implementation Method 2
in the presence of an aqueous base sufficiently strong to deprotonize the indole N—H and optionally a catalyst
Implementation Method 3
which process can be scaled up to large scale and/or industrial scale such as 10 kg or higher... purified to a crystalline free base form
Data Source
AI summary
The present invention relates to a process for preparing 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo-[2,3-b]quinoxaline, wherein said process is suitable for large scale synthesis.